Tvardi Therapeutics, Inc.

Tvardi Therapeutics, Inc.

Biotechnology • Healthcare • Sugar Land, TX, United States • TVRD (NCM)

Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in pre-clinical stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.

Stock Performance (90 Days)

Data through Dec 24, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Tvardi Therapeutics’ stock crashes on Phase II IPF flop - Clinical Trials Arena
Clinical Trials Arena • Oct 14
Tvardi Therapeutics (NASDAQ: TVRD) targets H1 2026 readouts for TTI-101 in HCC and TTI-109 - Stock Titan
Stock Titan • Nov 13
Tvardi (TVRD) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Nasdaq
Nasdaq • Nov 18
Why Tvardi Therapeutics (TVRD) Is Down 83.3% After Disappointing Phase 2 TTI-101 IPF Trial Results - Yahoo Finance
Yahoo Finance • Oct 14
Tvardi Therapeutics stock plummets as Oppenheimer slashes price target - Investing.com
Investing.com • Oct 13

Other Biotechnology Companies

View All →
CODEXIS, INC. logo Codexis, Inc.
1 layoff tracked
$144.5M market cap
VERTEX PHARMACEUTICALS INC / MA logo Vertex Pharmaceuticals Inc. / MA
$118.68B market cap
REGENERON PHARMACEUTICALS, INC. logo Regeneron Pharmaceuticals, Inc.
$82.72B market cap
ALNYLAM PHARMACEUTICALS, INC. logo Alnylam Pharmaceuticals, Inc.
$52.92B market cap
ARGENX SE logo Argenx SE
$52.62B market cap
INSMED Inc logo Insmed Inc.
$37.61B market cap

Frequently Asked Questions

Has Tvardi Therapeutics, Inc. had layoffs?
No layoff events have been recorded for Tvardi Therapeutics, Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does Tvardi Therapeutics, Inc. have?
Tvardi Therapeutics, Inc. has approximately 12 employees.
What industry is Tvardi Therapeutics, Inc. in?
Tvardi Therapeutics, Inc. operates in the Biotechnology industry, within the Healthcare sector.
Is Tvardi Therapeutics, Inc. a publicly traded company?
Yes, Tvardi Therapeutics, Inc. is publicly traded under the ticker symbol TVRD on the NCM. The company has a market capitalization of approximately $0.04 billion.
Where is Tvardi Therapeutics, Inc. headquartered?
Tvardi Therapeutics, Inc. is headquartered in Sugar Land, TX, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.